EU/3/17/1947

About

On 12 December 2017, orphan designation (EU/3/17/1947) was granted by the European Commission to NeuroVive Pharmaceutical AB, Sweden, for 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione (also known as KL1333) for the treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes.

In January 2021, NeuroVive Pharmaceutical AB changed name to Abliva AB.

Key facts

Active substance
2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione
Disease / condition
Treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes
Date of first decision
12/12/2017
Outcome
Positive
EU designation number
EU/3/17/1947

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Abliva AB
Scheelegatan 2
SE-223 81 Lund
Sweden
Tel. +46 46 275 62 20
E-mail: info@abliva.com 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating